Fermion Oy Fermion Oy

X
[{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Stifel","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Abeona Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            The proceeds will fund preparations for resubmission of Abeona's BLA and for commercialization of pz-cel (prademagene zamikeracel), an investigational autologous, COL7A1 gene-corrected epidermal sheets in development for recessive dystrophic epidermolysis bullosa.

            Lead Product(s): Prademagene Zamikeracel

            Therapeutic Area: Genetic Disease Product Name: EB-101

            Highest Development Status: Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Stifel

            Deal Size: $75.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering May 03, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY